ReportLinker
Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others.
New York, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By Product, By Application, By Regional Outlook and Forecast, 2022 2028" - https://www.reportlinker.com/p06322275/?utm_source=GNW These medications could greatly enhance human health. Protein distribution in appropriate amounts to the body to enable the precise functioning of various glands, as well as other organs in the body, is the basic concept behind protein therapy, which is conceptually related to gene therapy.
Genetically modified versions of naturally produced human proteins are called therapeutic proteins. They can be utilized to swap out proteins that are defective or lacking in a particular condition. They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness. The proteins produced by genetic engineering can be made to closely match the natural proteins they are meant to replace, or they can be improved by the addition of sugars and other compounds that prolong the proteins activity.
A protein that is defective or lacking in a certain condition can be replaced with therapeutic proteins. They can also increase the bodys production of a helpful protein to lessen the effects of illness or chemotherapy. The proteins produced by genetic engineering may closely resemble the natural proteins they are intended to replace, or they may be improved.
Covid-19 Impact Analysis
The COVID-19 pandemic severely hampered the economy all over the world. A number of businesses were significantly demolished by the abrupt emergence of the pandemic. Moreover, several manufacturing and production facilities were closed owing to the outbreak due to the lockdown imposed by various governments within their countries. The protein therapeutics market was also disrupted in the initial period of the pandemic. Lockdown caused major delays within the development and delivery of crucial medical supplies. Attributed to this, the production of therapeutic protein was impeded.
Market Growth Factors
An increase in the cases of cancer across the world
One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world. Any disease that can affect any region of the body is referred to as cancer. Neoplasms and malignant tumors are other words that are used to denote this disease. One characteristic of cancer is the quick development of aberrant cells that expand outside of their normal borders, infiltrate other body components, and eventually move to other organs. This process is known as metastasis. The main reason why cancer patients die is because of widespread metastases within their bodies.
Rising focus of governments and regulatory bodies in accelerating the process of approval for this practice
A significant number of people in various developed, as well as developing nations who suffer from uncommon and complex diseases, depend on plasma-derived therapies every day as essential, life-saving medications. The need for these treatments, in particular immunoglobulins, has grown significantly and is still growing on a global scale. Plasma-derived therapies are treatments made from human plasma through a fractionation procedure in which the pertinent plasma proteins are isolated. The single largest component of human blood is called plasma, which is made up of proteins, salts, enzymes, and water. Primary and secondary immunodeficiencies, bleeding disorders, inhibitor deficiencies, and other rare diseases are all treated with plasma-derived medicines.
Market Restraining Factors
High manufacturing and administration cost
A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies. Because of high product prices, some therapies that patients need for a speedy and complete recovery are no longer available. In several nations, prices are additionally governed by law. Through their authority over national healthcare organizations, which can cover a significant portion of the cost of distributing drugs to consumers, government bodies restrict costs.
Product Outlook
On the basis of Product, the Protein Therapeutics Market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. In 2021, the Insulin segment garnered a significant revenue share of the protein therapeutics market. The rise in the growth of the segment is majorly attributed to the increasing cases of diabetes all over the world. Insulin is a natural hormone, which is produced by the pancreas. The lack of production of this hormone is the factor that stimulates the diabetes level of the human body.
Application Outlook
By application, the Protein Therapeutics Market is segregated into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others. In 2021, the metabolic disorders segment procured the biggest revenue share of the protein therapeutics market. The rise in the growth of the segment is due to the exponential demand for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segments growth.
Regional Outlook
Region-wise, the Protein Therapeutics Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America held the largest revenue share of the protein therapeutics market. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. Moreover, North American countries are early adopters of several new technologies and approaches.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Protein Therapeutics Market. Companies such as Merck & Co., Inc. Amgen, Inc., Eli Lilly and Company are some of the key innovators in Protein Therapeutics Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
Recent Strategies Deployed in Protein Therapeutics Market
Partnership, Collaboration and Agreements:
Aug-2022: Merck came into a collaboration with Orna Therapeutics, a biotechnology company. Following this collaboration, the companies would work on the discovery, development, and commercialization of multiple programs, encompassing therapeutics and vaccines in the sector of infectious disease and oncology.
Mar-2022: Novo Nordisk joined hands with Massachusetts Institutes of Technology and Brigham and Womens Hospital. Through this collaboration, the company aimed to leverage the distinct prospect to bring new transformational solutions to patients by utilizing its distinct capabilities.
Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.
Jan-2022: Merck teamed up with Absci, the drug, and target discovery company. Following this collaboration, Merck aimed to leverage Abscis platform to utilize its compelling opportunity intending to develop new biologic candidates as well as explore complex protein expression.
Aug-2021: Eli Lilly and Company joined hands with Lycia Therapeutics, a biotechnology company. Following this collaboration, the companies aimed to focus on the development, manufacturing, and marketing of new targeted therapeutics leveraging the proprietary lysosomal targeting chimera protein degradation technology of Lycia.
Sep-2020: Merck collaborated with Seattle Genetics, an American biotechnology company. With this collaboration, the companies aimed to further expand the oncology portfolio of Merck in order to enhance the lives of cancer patients.
Acquisition and Mergers:
Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to integrate RSV investigational treatments of ReViral into its portfolio in order to acquire an offering of promising therapeutic candidates.
Nov-2021: Pfizer took over Trillium Therapeutics, a clinical-stage immuno-oncology company. This acquisition aimed to offer an impressive portfolio, including biologics, to Pfizer
Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobios antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.
Jul-2021: Eli Lilly and Company completed its acquisition of Protomer, a pre-clinical stage biotechnology company. Under this acquisition, the company aimed to help Protomer in enhancing its diabetes range with its innovative technology.
Feb-2021: Merck took over VelosBio, a privately held clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to boost its expanding oncology portfolio while also strengthening its long-term growth potential.
Aug-2020: Johnson & Johnson completed its acquisition of Momenta Pharmaceuticals, a biotechnology company. This acquisition aimed to strengthen Janssens position in the autoimmune diseases sector and offer a major catalyst for sustained growth of the company.
Approvals and Trials:
Sep-2020: Baxter International received the US FDA approval for its Clinimix and Clinimix E. The new formulations aimed to complement the offerings of medical formulations with their higher protein content.
Scope of the Study
Market Segments covered in the Report:
By Product
Monoclonal Antibodies
Human Growth Hormone
Fusion Protein
Insulin
Erythropoietin
Interferon
Follicle Stimulating Hormone
By Application
Metabolic Disorders
Immunologic Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others
By Geography
North America
o US
o Canada
o Mexico
o Rest of North America
Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA
Companies Profiled
Abbott Laboratories
Baxter International, Inc.
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly And Company
Merck & Co., Inc.
Johnson & Johnson (Janssen Global Services, LLC)
Pfizer, Inc.
Novo Nordisk A/S
Sanofi S.A.
Unique Offerings
- Viewpoint: Anti-GMO arguments seem silly after 28 years of false narratives about health harms and and genetic ... - Genetic Literacy Project - March 29th, 2024 [March 29th, 2024]
- Viewpoint: Here's how genetically engineered fruits and vegetables will soon emerge as a grocery store 'selling point ... - Genetic Literacy Project - March 29th, 2024 [March 29th, 2024]
- CRISPR Investments: What We Heard at World Agri-Tech - Seed World - March 29th, 2024 [March 29th, 2024]
- When SpaceX's Starship is ready to settle Mars, will we be? (op-ed) - Space.com - September 17th, 2023 [September 17th, 2023]
- Genome-wide promoter responses to CRISPR perturbations of ... - Nature.com - September 17th, 2023 [September 17th, 2023]
- Expanding the toolbox for RNA editing | ASU News - ASU News Now - September 17th, 2023 [September 17th, 2023]
- Electrical Engineer Named MIT Technology Review Innovator Under ... - University of California San Diego - September 17th, 2023 [September 17th, 2023]
- Can we rely on our 'moral force-field' to stop cloning going too far? - The National - September 17th, 2023 [September 17th, 2023]
- Otsuka Collaborates with ShapeTX for Development of AAV Gene ... - Pharmaceutical Technology Magazine - September 17th, 2023 [September 17th, 2023]
- Cancer discovery earns U of A grad the Breakthrough Prize - University of Alberta - September 17th, 2023 [September 17th, 2023]
- The Brave New World of synthetic humans | Gne Taylor - IAI - September 17th, 2023 [September 17th, 2023]
- Targeting Tumors with Photosynthetic Bacteria - Optics & Photonics News - September 17th, 2023 [September 17th, 2023]
- Artificial Photosynthesis Breakthrough Researchers Produce ... - SciTechDaily - September 17th, 2023 [September 17th, 2023]
- BASF patent on watermelons upheld: European Patent Office rejects ... - Bio Eco Actual - September 17th, 2023 [September 17th, 2023]
- Space Industry Is Growing Faster Than Its Workforce, Analysts Say - Slashdot - September 17th, 2023 [September 17th, 2023]
- New 'Inverse Vaccine' Shows Potential to Treat MS and Other ... - Slashdot - September 17th, 2023 [September 17th, 2023]
- Gene therapy: Donor DNA may protect babies from certain disorders - Medical News Today - May 18th, 2023 [May 18th, 2023]
- Viewpoint: Grim consequences of Greenpeace's war on ... - Genetic Literacy Project - May 18th, 2023 [May 18th, 2023]
- Predicting Diabetic Kidney Disease with the Use of a Novel Algorithm - Genetic Engineering & Biotechnology News - May 18th, 2023 [May 18th, 2023]
- Quantum biology on horizon? How futuristic physics theory could ... - Study Finds - May 18th, 2023 [May 18th, 2023]
- Scientists can collect human DNA from water, air, and basically ... - Earth.com - May 18th, 2023 [May 18th, 2023]
- The First Crispr-Edited Salad Is Here - WIRED - May 18th, 2023 [May 18th, 2023]
- Gene editing technology used to produce disease-resistant calf - Earth.com - May 18th, 2023 [May 18th, 2023]
- Neanderthals passed down their tall noses to modern humans ... - Livescience.com - May 18th, 2023 [May 18th, 2023]
- Squid Camouflage Inspires Human Invisibility: Is it Possible? - DISCOVER Magazine - May 18th, 2023 [May 18th, 2023]
- Mice Model Technologies Market Poised for 7.4% CAGR Growth, Reaching USD 3.2 Bn by 2031 | Transparency Market Research - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Google Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicine - CNBC - May 18th, 2023 [May 18th, 2023]
- How Fauci, scientists with ties to Wuhan lab persuaded the ... - U.S. Right to Know - May 18th, 2023 [May 18th, 2023]
- The Daunting Task of Cutting Heavy Metals from Baby Food - Undark Magazine - May 18th, 2023 [May 18th, 2023]
- Ingestible Device Profiles and Peers into the Microbiome and ... - Genetic Engineering & Biotechnology News - May 18th, 2023 [May 18th, 2023]
- X-Men Officially Names the Best Powers Any Mutant Can Have - Screen Rant - May 18th, 2023 [May 18th, 2023]
- 10 Forgotten Marvel Comics Characters That Debuted In The '80s - Screen Rant - May 18th, 2023 [May 18th, 2023]
- 18 Human Genetic Engineering - Clemson University - April 19th, 2023 [April 19th, 2023]
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 31st, 2023 [March 31st, 2023]
- What is Genetic Engineering? Types, Process & Applications - March 31st, 2023 [March 31st, 2023]
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 31st, 2023 [March 31st, 2023]
- Welcome to the UNC Department of Genetics | Department of Genetics - February 5th, 2023 [February 5th, 2023]
- Global Genetically Modified Crops Market Is Projected To Grow At A 6% Rate Through The Forecast Period - EIN News - February 5th, 2023 [February 5th, 2023]
- Science and History of GMOs and Other Food Modification Processes - February 2nd, 2023 [February 2nd, 2023]
- Genetics | History, Biology, Timeline, & Facts | Britannica - January 31st, 2023 [January 31st, 2023]
- Human genetics | Description, Chromosomes, & Inheritance - January 31st, 2023 [January 31st, 2023]
- Genetic testing - Mayo Clinic - January 31st, 2023 [January 31st, 2023]
- Genetic Disorders: What Are They, Types, Symptoms & Causes - January 31st, 2023 [January 31st, 2023]
- Colossal Biosciences Project to Revive the Prehistoric Woolly Mammoth Raises Staggering $60 Million Series A Funding - Nature World News - January 22nd, 2023 [January 22nd, 2023]
- 2023 is going to witness a surge in technology courses top courses that will remain in vogue - Times of India - January 22nd, 2023 [January 22nd, 2023]
- M.R.S. Rao birthday: All you need to know about the Padma Shri winning Indian scientist - Free Press Journal - January 22nd, 2023 [January 22nd, 2023]
- Russian cosmism - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Postgenderism - Wikipedia - January 8th, 2023 [January 8th, 2023]
- LessWrong - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Eliezer Yudkowsky - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Genetic Engineering Principles of Biology - December 26th, 2022 [December 26th, 2022]
- Engineering the Perfect Baby | MIT Technology Review - December 26th, 2022 [December 26th, 2022]
- Genetic Engineering Science Projects - Science Buddies - December 21st, 2022 [December 21st, 2022]
- DSI adoption at COP15 can financially help protect biodiversity in India: Experts - The Tribune India - December 21st, 2022 [December 21st, 2022]
- Tel Aviv University researchers demonstrate success of potential one-time vaccine to treat HIV/AIDS - ETHealthWorld - December 21st, 2022 [December 21st, 2022]
- Should You Buy 22nd Century Group Inc (XXII) Stock After it Has Risen 14.29% in a Week? - InvestorsObserver - October 28th, 2022 [October 28th, 2022]
- Home :: National Institute for Biotechnology and Genetic Engineering - October 11th, 2022 [October 11th, 2022]
- A recently discovered law of physics could help predict genetic mutations - October 11th, 2022 [October 11th, 2022]
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 11th, 2022 [October 11th, 2022]
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 11th, 2022 [October 11th, 2022]
- After 45 years of science-based art, Esther Klein Gallery winds down - WHYY - October 11th, 2022 [October 11th, 2022]
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 11th, 2022 [October 11th, 2022]
- The key to tastier beer might be mutant yeastwith notes of banana - Popular Science - October 11th, 2022 [October 11th, 2022]
- Why You'll Probably Never See Cotton Candy Grape Wine - Tasting Table - October 11th, 2022 [October 11th, 2022]
- Earth materials in technology The National - The National - October 11th, 2022 [October 11th, 2022]
- CULINARY THRILL SEEKING Proceed with caution. It's hotter than blazes season. - Port Arthur News - The Port Arthur News - October 11th, 2022 [October 11th, 2022]
- Give legal rights to animals, trees and rivers, say experts - The Guardian - October 11th, 2022 [October 11th, 2022]
- How yeast DNA may help protect astronauts from cosmic radiation in space - EastMojo - October 11th, 2022 [October 11th, 2022]
- Life finds a way, but should it? The ethics of genetic engineering - The Trinitonian - October 8th, 2022 [October 8th, 2022]
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 8th, 2022 [October 8th, 2022]
- Gene Therapy Hits Its Stride in the Clinic - Genetic Engineering & Biotechnology News - October 8th, 2022 [October 8th, 2022]
- GWAS, MWAS and mGWAS provide insights into precision agriculture based on genotype-dependent microbial effects in foxtail millet - Nature.com - October 8th, 2022 [October 8th, 2022]
- Making Sense of the Latest Apple-iPhone News - The Motley Fool - October 8th, 2022 [October 8th, 2022]
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 8th, 2022 [October 8th, 2022]
- GMO: Everything you need to know about lifting ban - FarmKenya Initiative - The Standard - October 8th, 2022 [October 8th, 2022]
- Century Therapeutics to Present at the SITC 37th Annual Meeting - Yahoo Finance - October 8th, 2022 [October 8th, 2022]
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 8th, 2022 [October 8th, 2022]
- Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting -... - October 8th, 2022 [October 8th, 2022]
- Explained: How scientists engineered mosquitoes that will cut the transmission of malaria - Firstpost - October 8th, 2022 [October 8th, 2022]
- Here Are the Biggest Health Industry News Items of 2022 So Far - DocWire News - October 8th, 2022 [October 8th, 2022]